Exact Mass: 369.1916292
Exact Mass Matches: 369.1916292
Found 500 metabolites which its exact mass value is equals to given mass value 369.1916292,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
alpha-Allocryptopine
Alpha-allocryptopine, also known as alpha-fagarine or beta-homochelidonine, is a member of the class of compounds known as protopine alkaloids. Protopine alkaloids are alkaloids with a structure based on a tricyclic protopine formed by oxidative ring fission of protoberberine N-metho salts. Alpha-allocryptopine is practically insoluble (in water) and an extremely weak acidic compound (based on its pKa). Alpha-allocryptopine can be found in barley, which makes alpha-allocryptopine a potential biomarker for the consumption of this food product. Allocryptopine is a dibenzazecine alkaloid, an organic heterotetracyclic compound, a tertiary amino compound, a cyclic ketone, a cyclic acetal and an aromatic ether. Allocryptopine is a natural product found in Zanthoxylum beecheyanum, Berberis integerrima, and other organisms with data available. See also: Sanguinaria canadensis root (part of). KEIO_ID A137; [MS2] KO008812 KEIO_ID A137; [MS3] KO008813 KEIO_ID A137 Allocryptopine, a derivative of tetrahydropalmatine, is extracted from Macleaya cordata (Thunb.) Pers. Papaveraceae. Allocryptopine has antiarrhythmic effects and potently blocks human ether-a-go-go related gene (hERG) current[1][2]. Allocryptopine, a derivative of tetrahydropalmatine, is extracted from Macleaya cordata (Thunb.) Pers. Papaveraceae. Allocryptopine has antiarrhythmic effects and potently blocks human ether-a-go-go related gene (hERG) current[1][2].
Heroin
C21H23NO5 (369.15761480000003)
A morphinane alkaloid that is morphine bearing two acetyl substituents on the O-3 and O-6 positions. As with other opioids, heroin is used as both an analgesic and a recreational drug. Frequent and regular administration is associated with tolerance and physical dependence, which may develop into addiction. Its use includes treatment for acute pain, such as in severe physical trauma, myocardial infarction, post-surgical pain, and chronic pain, including end-stage cancer and other terminal illnesses. N - Nervous system > N07 - Other nervous system drugs > N07B - Drugs used in addictive disorders > N07BC - Drugs used in opioid dependence D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist > C1657 - Opiate D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics CONFIDENCE standard compound; INTERNAL_ID 1533
Corydalin
C22H27NO4 (369.19399820000007)
D004791 - Enzyme Inhibitors Corydaline ((+)-Corydaline), an isoquinoline alkaloid isolated from Corydalis yanhusuo, is an AChE inhibitor with an IC50 of 226 μM. Corydaline is a μ-opioid receptor (Ki of 1.23 μM) agonist and inhibits enterovirus 71 (EV71) replication (IC50 of 25.23 μM). Corydaline has anti-angiogenic, anti-allergic and gastric-emptying and antinociceptive activities[1][2][3]. Corydaline ((+)-Corydaline), an isoquinoline alkaloid isolated from Corydalis yanhusuo, is an AChE inhibitor with an IC50 of 226 μM. Corydaline is a μ-opioid receptor (Ki of 1.23 μM) agonist and inhibits enterovirus 71 (EV71) replication (IC50 of 25.23 μM). Corydaline has anti-angiogenic, anti-allergic and gastric-emptying and antinociceptive activities[1][2][3]. Corydaline ((+)-Corydaline), an isoquinoline alkaloid isolated from Corydalis yanhusuo, is an AChE inhibitor with an IC50 of 226 μM. Corydaline is a μ-opioid receptor (Ki of 1.23 μM) agonist and inhibits enterovirus 71 (EV71) replication (IC50 of 25.23 μM). Corydaline has anti-angiogenic, anti-allergic and gastric-emptying and antinociceptive activities[1][2][3].
Fumaricine
C21H23NO5 (369.15761480000003)
Trimetrexate
C19H23N5O3 (369.18008080000004)
A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. [PubChem] P - Antiparasitic products, insecticides and repellents > P01 - Antiprotozoals > P01A - Agents against amoebiasis and other protozoal diseases C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2153 - Dihydrofolate Reductase Inhibitor D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists D000890 - Anti-Infective Agents > D000935 - Antifungal Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents Same as: D06238
Epanolol
C20H23N3O4 (369.16884780000004)
C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AB - Beta blocking agents, selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Same as: D06646
Amisulpride
Amisulpride (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist. D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AL - Benzamides C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist Amisulpride is a dopamine D2/D3 receptor antagonist with Kis of 2.8 and 3.2 nM for human dopamine D2 and D3, respectively.
Romucosine D
C21H23NO5 (369.15761480000003)
Romucosine D is found in alcoholic beverages. Romucosine D is an alkaloid from Rollinia mucosa (biriba). Alkaloid from Rollinia mucosa (biriba). Romucosine D is found in alcoholic beverages and fruits.
7-Hydroxydehydroglaucine
C21H23NO5 (369.15761480000003)
7-Hydroxydehydroglaucine is found in beverages. 7-Hydroxydehydroglaucine is an alkaloid from Annona purpurea (soncoya). Alkaloid from Annona purpurea (soncoya). 7-Hydroxydehydroglaucine is found in beverages and fruits.
Cilostazol
Cilostazol is a medication used in the alleviation of the symptom of intermittent claudication in individuals with peripheral vascular disease. It is manufactured by Otsuka Pharmaceutical Co. under the trade name Pletal. Although drugs similar to cilostazol have increased the risk of death in patients with congestive heart failure, studies of significant size have not addressed people without the disease. [Wikipedia] B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors > D058987 - Phosphodiesterase 3 Inhibitors D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor D050299 - Fibrin Modulating Agents D020011 - Protective Agents
3,4-dimethylidenedecanedioylcarnitine
3,4-dimethylidenedecanedioylcarnitine is an acylcarnitine. More specifically, it is an 3,4-dimethylidenedecanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,4-dimethylidenedecanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,4-dimethylidenedecanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-2,10-dienedioylcarnitine
Dodeca-2,10-dienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-2,10-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-2,10-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-2,10-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-7,9-dienedioylcarnitine
Dodeca-7,9-dienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-7,9-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-7,9-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-7,9-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-5,9-dienedioylcarnitine
Dodeca-5,9-dienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-5,9-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-5,9-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-5,9-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-3,10-dienedioylcarnitine
Dodeca-3,10-dienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-3,10-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-3,10-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-3,10-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-5,8-dienedioylcarnitine
Dodeca-5,8-dienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-5,8-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-5,8-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-5,8-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-6,8-dienedioylcarnitine
Dodeca-6,8-dienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-6,8-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-6,8-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-6,8-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-7,10-dienedioylcarnitine
Dodeca-7,10-dienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-7,10-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-7,10-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-7,10-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-5,10-dienedioylcarnitine
Dodeca-5,10-dienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-5,10-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-5,10-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-5,10-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-4,9-dienedioylcarnitine
Dodeca-4,9-dienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-4,9-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-4,9-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-4,9-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(6E)-Dodeca-2,6-dienedioylcarnitine
(6E)-Dodeca-2,6-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (6E)-dodeca-2,6-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6E)-Dodeca-2,6-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (6E)-Dodeca-2,6-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-6,9-dienedioylcarnitine
Dodeca-6,9-dienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-6,9-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-6,9-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-6,9-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-4,8-dienedioylcarnitine
Dodeca-4,8-dienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-4,8-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-4,8-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-4,8-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-4,10-dienedioylcarnitine
Dodeca-4,10-dienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-4,10-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-4,10-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-4,10-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-3,9-dienedioylcarnitine
Dodeca-3,9-dienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-3,9-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-3,9-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-3,9-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-5,7-dienedioylcarnitine
Dodeca-5,7-dienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-5,7-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-5,7-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-5,7-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Dodeca-8,10-dienedioylcarnitine
Dodeca-8,10-dienedioylcarnitine is an acylcarnitine. More specifically, it is an dodeca-8,10-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Dodeca-8,10-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine Dodeca-8,10-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
5-Fluoro-3-[3-[4-(5-methoxypyrimidin-4-yl)piperazin-1-yl]propyl]-1H-indole
Bulaquine
C21H27N3O3 (369.20523120000007)
Corydalin
C22H27NO4 (369.19399820000007)
D004791 - Enzyme Inhibitors
Galunisertib
C22H19N5O (369.15895240000003)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
4-Ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone
(2S)-2-Amino-3-[(2S,3R)-2-amino-3-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]oxybutanoyl]oxypropanoic acid
Corydaline
C22H27NO4 (369.19399820000007)
Corydaline is an isoquinoline alkaloid and a member of isoquinolines. Corydaline is a natural product found in Corydalis remota, Corydalis saxicola, and other organisms with data available. D004791 - Enzyme Inhibitors Corydaline ((+)-Corydaline), an isoquinoline alkaloid isolated from Corydalis yanhusuo, is an AChE inhibitor with an IC50 of 226 μM. Corydaline is a μ-opioid receptor (Ki of 1.23 μM) agonist and inhibits enterovirus 71 (EV71) replication (IC50 of 25.23 μM). Corydaline has anti-angiogenic, anti-allergic and gastric-emptying and antinociceptive activities[1][2][3]. Corydaline ((+)-Corydaline), an isoquinoline alkaloid isolated from Corydalis yanhusuo, is an AChE inhibitor with an IC50 of 226 μM. Corydaline is a μ-opioid receptor (Ki of 1.23 μM) agonist and inhibits enterovirus 71 (EV71) replication (IC50 of 25.23 μM). Corydaline has anti-angiogenic, anti-allergic and gastric-emptying and antinociceptive activities[1][2][3]. Corydaline ((+)-Corydaline), an isoquinoline alkaloid isolated from Corydalis yanhusuo, is an AChE inhibitor with an IC50 of 226 μM. Corydaline is a μ-opioid receptor (Ki of 1.23 μM) agonist and inhibits enterovirus 71 (EV71) replication (IC50 of 25.23 μM). Corydaline has anti-angiogenic, anti-allergic and gastric-emptying and antinociceptive activities[1][2][3].
Cryptopine
C21H23NO5 (369.15761480000003)
Origin: Plant; SubCategory_DNP: Alkaloids derived from anthranilic acid, Cryptolepine-type alkaloids relative retention time with respect to 9-anthracene Carboxylic Acid is 0.618 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.612
Jacoline
A pyrrolizine alkaloid obtained from senecionine by formal addition of hydrogen peroxide across the ethylidene double bond.
2-(2-Hydroxy-4-methoxyphenyl)-5,8-dimethoxy-3-propyl-4(1H)-quinolinone
C21H23NO5 (369.15761480000003)
1-(cyclohexylmethyl)-N-(4,4-dimethyl-2-oxotetrahydrofuran-3-yl)-1h-indazole-3-carboxamide
C21H27N3O3 (369.20523120000007)
5-{[2-imino-4-(4-methoxybenzyl)-1-methyl-1,2-dihydro-1H-imidazol-5-yl]methyl}-2-methoxy-1,3-benzenediol|naamine C
C20H23N3O4 (369.16884780000004)
1,9,10-trimethoxy-2,3-methylenedioxyaporphine
C21H23NO5 (369.15761480000003)
(12Xi,13Xi,14Xi,15Xi)-12,15,18-Trihydroxy-14-methyl-15,20-dihydro-21-nor-senecionan-11,16-dion|(12Xi,13Xi,14Xi,15Xi)-12,15,18-trihydroxy-14-methyl-15,20-dihydro-21-nor-senecionan-11,16-dione|12,15,18-trihydroxy-14xi-methyl-(12xiH,13xiH,15xiH)-15,20-dihydro-21-nor-senecionane-11,16-dione|Sceleratin
N,N-dimethyl-N-deacetyl-(-)-cornigerine
C21H23NO5 (369.15761480000003)
N-(4-methoxy-cis-cinnamoyl)-3-(4-methoxyphenyl)-L-alanine methyl ester
C21H23NO5 (369.15761480000003)
(+/-)-celafurine|9-(furan-3-carbonyl)-2-phenyl-1,5,9-triaza-cyclotridecan-4-one|Celafurin
C21H27N3O3 (369.20523120000007)
2,3-Dihydro-4-hydroxycapitavine|trihydroxy-5,7,4 (methyl-1 piperidinyl-2)-6 flavanone
C21H23NO5 (369.15761480000003)
Allocryptopine
C21H23NO5 (369.15761480000003)
Allocryptopine is a dibenzazecine alkaloid, an organic heterotetracyclic compound, a tertiary amino compound, a cyclic ketone, a cyclic acetal and an aromatic ether. Allocryptopine is a natural product found in Zanthoxylum beecheyanum, Berberis integerrima, and other organisms with data available. See also: Sanguinaria canadensis root (part of). IPB_RECORD: 788; CONFIDENCE confident structure Allocryptopine, a derivative of tetrahydropalmatine, is extracted from Macleaya cordata (Thunb.) Pers. Papaveraceae. Allocryptopine has antiarrhythmic effects and potently blocks human ether-a-go-go related gene (hERG) current[1][2]. Allocryptopine, a derivative of tetrahydropalmatine, is extracted from Macleaya cordata (Thunb.) Pers. Papaveraceae. Allocryptopine has antiarrhythmic effects and potently blocks human ether-a-go-go related gene (hERG) current[1][2].
2-(2-hydroxy-4-methoxyphenyl)-5,8-dimethoxy-3-propyl-1h-quinolin-4-one
C21H23NO5 (369.15761480000003)
(+)-isomalbrancheamide B|(5aS,12aS,13aS)-8-chloro-12,12-dimethyl-2,3,5,6,11,12,12a,13-octahydro-1H-5a,13a-(epiminomethano)indolizino[7,6-b]carbazol-14-one|isomalbrancheamide B
1,2-Dimethoxy-7-methyl-5H,6H,8H,11H,14H-benzo[1,2-4,5]azecino[9,8-2,1]benzo[4,5-d]1,3-dioxolan-15-one
C21H23NO5 (369.15761480000003)
2-benzamido-1-(4-methoxyphenyl)ethyl hexanoate|zanthorhetsamide
C22H27NO4 (369.19399820000007)
N-methyl-7-O-beta-D-glucopyranosyl-alpha-homonojirimycin
C14H27NO10 (369.16348819999996)
1,2-Dimethoxy-6-methyl-5,7,8,15-tetrahydro-6H-benzo[c][1,3]dioxolo[4,5:4,5]benzo[1,2-g]azecin-14-one
C21H23NO5 (369.15761480000003)
2,3-methanediyldioxy-4,6-dimethoxy-17-methyl-10a-homo-morphina-5,8(14)-dien-7-one|Alkaloid CC-20|alkaloid CC-20 (Colchicum cornigerum)
C21H23NO5 (369.15761480000003)
(7Xi,8S)-8,6-dimethoxy-2-methyl-6,8,3,4-tetrahydro-2H-spiro[indeno[4,5-d][1,3]dioxole-7,1-isoquinolin]-7-ol|Fumaritridin
C21H23NO5 (369.15761480000003)
didehydrotuberostemonine A|rel-(8R,8aS,11S,11aR)-8-ethyl-5,6,8,8a,11,11a-hexahydro-11-methyl-2-[(2S,4S)-tetrahydro-4-methyl-5-oxofuran-2-yl]azepino[3,2,1-hi]furo[3,2-e]indol-10(4H)-one
C22H27NO4 (369.19399820000007)
8,9,13-trimethoxy-14-methyl-5,6,11,12-tetrahydro-5,11-epiazano-benzo[5,6]cycloocta[1,2:4,5]benzo[1,2-d][1,3]dioxole
C21H23NO5 (369.15761480000003)
(3-Ethylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone
Palmatine
C21H23NO5 (369.15761480000003)
Palmatine hydroxide is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC50s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine hydroxide can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC50 of 96 μM. Palmatine hydroxide shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities[1][2][3][4][5]. Palmatine hydroxide is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC50s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine hydroxide can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC50 of 96 μM. Palmatine hydroxide shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities[1][2][3][4][5].
amisulpride
C17H27N3O4S (369.17221820000003)
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AL - Benzamides C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist CONFIDENCE standard compound; EAWAG_UCHEM_ID 2852 EAWAG_UCHEM_ID 2852; CONFIDENCE standard compound CONFIDENCE standard compound; INTERNAL_ID 2142 Amisulpride is a dopamine D2/D3 receptor antagonist with Kis of 2.8 and 3.2 nM for human dopamine D2 and D3, respectively.
Cilostazol
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors > D058987 - Phosphodiesterase 3 Inhibitors D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D002491 - Central Nervous System Agents > D018696 - Neuroprotective Agents C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D006401 - Hematologic Agents > D005343 - Fibrinolytic Agents C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor D050299 - Fibrin Modulating Agents D020011 - Protective Agents
Diacetylmorphine (Heroin)
C21H23NO5 (369.15761480000003)
CONFIDENCE standard compound; INTERNAL_ID 1533
Fagarine I
C21H23NO5 (369.15761480000003)
Origin: Plant; SubCategory_DNP: Isoquinoline alkaloids, Morphine alkaloids, Cryptopine alkaloids Allocryptopine, a derivative of tetrahydropalmatine, is extracted from Macleaya cordata (Thunb.) Pers. Papaveraceae. Allocryptopine has antiarrhythmic effects and potently blocks human ether-a-go-go related gene (hERG) current[1][2]. Allocryptopine, a derivative of tetrahydropalmatine, is extracted from Macleaya cordata (Thunb.) Pers. Papaveraceae. Allocryptopine has antiarrhythmic effects and potently blocks human ether-a-go-go related gene (hERG) current[1][2].
PC(3:0/3:0)
C14H28NO8P (369.15524580000005)
Dipropionylphosphatidylcholine
C14H28NO8P (369.15524580000005)
PC(7:0/0:0)
PC(7:0/0:0)[U]
PC(0:0/7:0)
PC(0:0/7:0)[U]
Pramanicin
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
7-Hydroxydehydroglaucine
C21H23NO5 (369.15761480000003)
Romucosine D
C21H23NO5 (369.15761480000003)
2-(2-ethylhexyl)-6,7-dimethoxy-1H-benz[de]isoquinoline-1,3(2H)-dione
C22H27NO4 (369.19399820000007)
Acetamide, N-cycloheptyl-2-[(5-methyl-5H-1,2,4-triazino[5,6-b]indol-3-yl)thio]- (9CI)
(R)-4-(4-(BENZYLOXY)PHENYL)-1-(1-PHENYLETHYL)-1,2,3,6-TETRAHYDROPYRIDINE
ETHYL 6-AMINO-5-CYANO-2-METHYL-4-(4-MORPHOLINOPHENYL)-4H-PYRAN-3-CARBOXYLATE
C20H23N3O4 (369.16884780000004)
dibutyl (Z)-but-2-enedioate,(E)-2,5-dimethylhex-2-enoate
C20H33O6- (369.22770180000003)
N4-(3-aminophenyl)-5-fluoro-N2-(4-(2-methoxyethoxy)phenyl)pyrimidine-2,4-diamine
ERYTHRO-N-BOC-O-BENZYL-L-TYROSINE EPOXIDE
C22H27NO4 (369.19399820000007)
tert-Butyl 4-((tosyloxy)methyl)piperidine-1-carboxylate
tert-butyl 3-((p-tolylsulfonyloxy)Methyl)piperidine-1-carboxylate
9-Phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-9H-carbazole
2-[4-(Dibutylamino)-2-hydroxybenzoyl]benzoic acid
C22H27NO4 (369.19399820000007)
9-Phenyl-9H-carbazole-3-boronic acid pinacol ester
Pirodavir
C21H27N3O3 (369.20523120000007)
C254 - Anti-Infective Agent > C281 - Antiviral Agent
Tetrabutylammonium iodide
D013501 - Surface-Active Agents > D003902 - Detergents
1-(2-methoxyphenyl)-2-(dicyclohexylphosphino)pyrrole
1-(4-AMINO-PHENYL)-AZETIDINE-3-CARBOXYLICACIDMETHYLESTER
C23H28ClNO (369.18593080000005)
9-[4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-9H-carbazole
Sodium N-dodecanoyl-L-phenlyalaninate
C21H32NNaO3 (369.22797620000006)
9-Ethyl-3-(N-butyl-N-phenylhydrazonomethyl)carbazole
2,6-Bis[1-[(2,6-diMethylphenyl)iMino]ethyl]pyridine
6,7-bis(2-methoxyethoxy)-N-phenylquinazolin-4-amine
C20H23N3O4 (369.16884780000004)
5-Amino-1-Boc-3,4,5,6-tetrahydro-2H-[2,4]bipyridinyl oxalate
Saxagliptin hydrochloride Monohydrate
C18H25N3O2.HCl.H2O (369.18190880000003)
(1R,4R)-4-((TERT-BUTOXYCARBONYL)AMINO)CYCLOHEXYL 4-METHYLBENZENESULFONATE
1-(4-(2-methyl-6-oxopiperidin-1-yl)phenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-one
C21H27N3O3 (369.20523120000007)
1(2H)-PyriMidineacetic acid, 4-[bis[(1,1-diMethylethoxy)carbonyl]aMino]-2-oxo-
9H-fluoren-9-ylmethyl N-[(2S)-1-hydroxy-3-[(2-methylpropan-2-yl)oxy]propan-2-yl]carbamate
C22H27NO4 (369.19399820000007)
(4-Cyclobutyl-1,4-diazepan-1-yl)(6-(4-fluorophenoxy)pyridin-3-yl)methanone
Butanoic acid, 2-(bis(2-methoxyethyl)amino)-, 2,6-dimethoxy-4-methylphenyl ester, (2R)-
Bulaquine
C21H27N3O3 (369.20523120000007)
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent
(15alpha,20R)-12,15,20-Trihydroxy-15,20-dihydrosenecionan-11,16-dione
2-Amino-1-[2-(4-morpholinyl)ethyl]-3-pyrrolo[3,2-b]quinoxalinecarboxylic acid ethyl ester
C19H23N5O3 (369.18008080000004)
L-Phenylalanine, L-phenylalanylglycyl-
C20H23N3O4 (369.16884780000004)
8-(2,5-Dimethoxy-benzyl)-2-fluoro-9-pent-9H-purin-6-ylamine
(3R,4S)-1-[(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]-4-[(benzylsulfanyl)methyl]pyrrolidin-3-ol
trimetrexate
C19H23N5O3 (369.18008080000004)
P - Antiparasitic products, insecticides and repellents > P01 - Antiprotozoals > P01A - Agents against amoebiasis and other protozoal diseases C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2153 - Dihydrofolate Reductase Inhibitor D004791 - Enzyme Inhibitors > D005493 - Folic Acid Antagonists D000890 - Anti-Infective Agents > D000935 - Antifungal Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents Same as: D06238
Galunisertib
C22H19N5O (369.15895240000003)
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
Epanolol
C20H23N3O4 (369.16884780000004)
C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AB - Beta blocking agents, selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Same as: D06646
Strictosidine aglycone(1+)
Conjugate acid of strictosidine aglycone arising from deprotonation of the secondary amino group; major species at pH 7.3.
3alpha-Sulfooxy-5alpha-androstan-17-one
C19H29O5S- (369.17356040000004)
(2R)-2-amino-3-[[(1S,2R,4R,7E,11S)-4,8-dimethyl-13-oxo-3,14-dioxatricyclo[9.3.0.02,4]tetradec-7-en-12-yl]methylsulfanyl]propanoic acid
Canadaline
C21H23NO5 (369.15761480000003)
A natural product found in Corydalis cava and Hydrastis canadensis.
2-[(4,4-Dimethyl-2,6-dioxocyclohexyl)-(3-pyridinyl)methyl]-5,5-dimethylcyclohexane-1,3-dione
C22H27NO4 (369.19399820000007)
19-hydroxyprostaglandin H1(1-)
C20H33O6- (369.22770180000003)
A prostaglandin carboxylic acid anion that is the conjugate base of 19-hydroxyprostaglandin H1, obtained by deprotonation of the carboxy group; major species at pH 7.3.
thromboxane B2(1-)
C20H33O6- (369.22770180000003)
A thromboxane anion that is the conjugate base of thromboxane B2, obtained by deprotonation of the carboxy group; major species at pH 7.3.
2-[(2-acetamido-1-oxoethyl)amino]-N-(4-methoxyphenyl)-2-(4-methylphenyl)acetamide
C20H23N3O4 (369.16884780000004)
N-[4-({2-[(2,5-dimethylphenoxy)acetyl]hydrazino}carbonyl)phenyl]propanamide
C20H23N3O4 (369.16884780000004)
5-tert-butyl-N-(4-fluorophenyl)-2-[(4-fluorophenyl)methyl]-3-pyrazolecarboxamide
1-(2,6-Dimethylphenyl)-3-[[1-(4-methoxyphenyl)-3-pyrrolidinyl]methyl]thiourea
C21H27N3OS (369.18747320000006)
3,4,5-trimethoxy-N-[2-(1-methyl-2-benzimidazolyl)ethyl]benzamide
C20H23N3O4 (369.16884780000004)
3-Oxo-5alpha-androstan-17beta-yl sulfate
C19H29O5S- (369.17356040000004)
6-linalyl-2-O,3-dimethylflaviolin-7-olate
An organic anion that is the conjugate base of 6-linalyl-2-O,3-dimethylflaviolin, obtained by deprotonation of the 7-hydroxy group. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).
1,3-Dimethyl-8-[[methyl-(phenylmethyl)amino]methyl]-7-(2-methylpropyl)purine-2,6-dione
4-(9H-fluoren-9-yl)-N-phenyl-1-piperazinecarboxamide
3-nitro-4-(2-oxolanylmethylamino)-N-(2-phenylethyl)benzamide
C20H23N3O4 (369.16884780000004)
(2S)-9-(furan-3-carbonyl)-2-phenyl-1,5,9-triazacyclotridecan-4-one
C21H27N3O3 (369.20523120000007)
N-(2-methyl-5-nitrophenyl)-4,6-bis(1-pyrrolidinyl)-1,3,5-triazin-2-amine
1-[4-[4-[(3,4-Dimethoxyphenyl)methylamino]phenyl]-1-piperazinyl]ethanone
C21H27N3O3 (369.20523120000007)
6,10-Dimethyl-N-(2-morpholin-4-ylethyl)-2-oxo-1,6,8-triazatricyclo[7.4.0.03,7]trideca-3(7),4,8,10,12-pentaene-5-carboxamide
C19H23N5O3 (369.18008080000004)
Hoerhammericine(1+)
An ammonium ion derivative resulting from the protonation of the tertiary amino group of hoerhammericine. The major species at pH 7.3. Note that the stereoconfiguration of the epoxy group is based on CHEBI:144374, and of the 19 hydroxy group on CHEBI:144372 (the same enzyme produces the two).
7-{(1R,4S,5R,6R)-6-[(1E,3S)-3-hydroperoxyoct-1-en-1-yl]-2,3-dioxabicyclo[2.2.1]heptan-5-yl}heptanoate
C20H33O6- (369.22770180000003)
17-Oxo-5alpha-androstan-3beta-yl sulfate
C19H29O5S- (369.17356040000004)
1-(2,4-dimethylphenyl)-3-[(E)-[4-(3-methylbutoxy)phenyl]methylideneamino]thiourea
C21H27N3OS (369.18747320000006)
2-O-(N-acetyl-alpha-D-galactosaminyl)-L-fucitol
C14H27NO10 (369.16348819999996)
A 2-deoxy-D-galactoside consisting of N-acetyl-D-galactosamine attached to L-fucitol via an alpha-(1->2)-linkage.
1-[4-(difluoromethoxy)phenyl]-3-(4-methylphenyl)-6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-4-ium
C22H23F2N2O+ (369.17783519999995)
N-[3-(1-imidazolyl)propyl]-2-phenyl-4-benzofuro[3,2-d]pyrimidinamine
C22H19N5O (369.15895240000003)
N-[[(2S,3S,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-2-pyridinecarboxamide
C20H23N3O4 (369.16884780000004)
N-[[(2R,3R,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-2-pyridinecarboxamide
C20H23N3O4 (369.16884780000004)
N-[[(2S,3R,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-2-pyridinecarboxamide
C20H23N3O4 (369.16884780000004)
2-cyclopropyl-1-[(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
C21H27N3O3 (369.20523120000007)
N-[[(2R,3S,4S)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-2-pyridinecarboxamide
C20H23N3O4 (369.16884780000004)
N-[[(2R,3S,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-2-pyridinecarboxamide
C20H23N3O4 (369.16884780000004)
N-[[(2R,3R,4R)-4-(hydroxymethyl)-1-(2-methoxy-1-oxoethyl)-3-phenyl-2-azetidinyl]methyl]-2-pyridinecarboxamide
C20H23N3O4 (369.16884780000004)
N-[[(2R,3S,4R)-4-(hydroxymethyl)-3-[4-(3-pyridinyl)phenyl]-2-azetidinyl]methyl]-N-(2-methoxyethyl)acetamide
C21H27N3O3 (369.20523120000007)
2-cyclopropyl-1-[(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-1-spiro[2,3-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]ethanone
C21H27N3O3 (369.20523120000007)
[(1R,5S)-7-[4-(3-methylphenyl)phenyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]-pyridin-4-ylmethanone
(-)-Voacangine(1+)
An ammonium ion derivative resulting from the protonation of the tertiary amino group of (-)-voacangine. The major species at pH 7.3.
6-oxoprostaglandin F1alpha(1-)
C20H33O6- (369.22770180000003)
A prostaglandin carboxylic acid anion that is the conjugate base of 6-oxoprostaglandin F1alpha, obtained by deprotonation of the carboxy group; major species at pH 7.3.
N-Ethyl-2,3,5,6-tetrahydro-4H,13H-15-oxa-3a,8-diaza-1H-dibenzo[a,hi]naphthacene-13-imine
N-[(2S,3R,4S,5R)-1,3,4,5-Tetrahydroxy-6-[(2R,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyhexan-2-yl]acetamide
C14H27NO10 (369.16348819999996)
(5S,6Z,8E,12S,14Z)-5,12,20,20-tetrahydroxyicosa-6,8,14-trienoate
C20H33O6- (369.22770180000003)
(2-Hydroxy-3-octoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
2,3-Di(propanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate
C14H28NO8P (369.15524580000005)
2-Aminoethyl (2-hydroxy-3-undecoxypropyl) hydrogen phosphate
[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] decanoate
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] acetate
(3-Acetyloxy-2-butanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C14H28NO8P (369.15524580000005)
[1-Acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] heptanoate
C14H28NO8P (369.15524580000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] hexanoate
C14H28NO8P (369.15524580000005)
[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] pentanoate
C14H28NO8P (369.15524580000005)
2-[(2-Acetamido-3-hydroxyoctoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-heptanoyl-sn-glycero-3-phosphocholine
A 2-acyl-sn-glycero-3-phosphocholine in which the acyl group is specified as heptanoyl.
1,2-dipropionyl-sn-glycero-3-phosphocholine
C14H28NO8P (369.15524580000005)
5alpha-dihydrotestosterone sulfate(1-)
C19H29O5S (369.17356040000004)
A steroid sulfate oxoanion that is the conjugate base of 5alpha-dihydrotestosterone sulfate, obtained by deprotonation of the sulfo group; major species at pH 7.3.
androsterone sulfate(1-)
C19H29O5S (369.17356040000004)
A steroid sulfate oxoanion that is the conjugate base of androsterone sulfate, obtained by deprotonation of the sulfo group; major species at pH 7.3.
20-hydroxyprostaglandin E1(1-)
A prostaglandin carboxylic acid anion that is the conjugate base of 20-hydroxyprostaglandin E1, obtained by deprotonation of the carboxy group; major species at pH 7.3.
Gly-Phe-Phe
C20H23N3O4 (369.16884780000004)
A tripeptide composed of one glycine and two L-phenylalanine residues joined in sequence
Celafurine
C21H27N3O3 (369.20523120000007)
A cyclic spermidine alkaloid that is 2-phenyl-1,5,9-triazacyclotridecan-4-one in which the amino hydrogen at position 9 has been replaced by a furan-3-carbonyl group.
prostaglandin G1(1-)
A prostaglandin carboxylic acid anion that is the conjugate base of prostaglandin G1, obtained by deprotonation of the carboxy group; major species at pH 7.3.
epiandrosterone sulfate(1-)
C19H29O5S (369.17356040000004)
A steroid sulfate oxoanion that is the conjugate base of epiandrosterone sulfate, obtained by deprotonation of the sulfo group; major species at pH 7.3.
LPE(10:0)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(S)-Amisulpride
C17H27N3O4S (369.17221820000003)
(S)-Amisulpride (Esamisulpride) is a potent dopamine D2/D3 receptor antagonist. (S)-Amisulpride is an antagonist at the 5-HT7 receptor with a KI of 900 nM. (S)-Amisulpride has antipsychotic and antidepressant effects[1][2].
Aramisulpride
C17H27N3O4S (369.17221820000003)
Aramisulpride is a dopamine D2 receptor and serotonin receptor antagonist used for the research of metabolic disorders[1].
MAGL-IN-1
C22H24FNO3 (369.17401259999997)
MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC50 of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays[1].
VU0357017 (hydrochloride)
C18H28ClN3O3 (369.1819088000001)
VU0357017 hydrochloride (CID-25010775) is a potent, selective and brain-penetrant allosteric agonist of M1 muscarinic acetylcholine receptor, with an EC50 of 477 nM. VU0357017 hydrochloride is highly selective for M1 and has no activity at M2-M5 up to the highest concentrations tested (30 μM). VU0357017 hydrochloride can be used for the research of Alzheimer’s disease and schizophrenia[1][2][3].
(1r,4r,5r,6r,16r)-5,6-dihydroxy-6-(hydroxymethyl)-4-isopropyl-5-methyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-ene-3,7-dione
(2e)-n-[(2r)-2-(acetyloxy)-2-(3,4-dimethoxyphenyl)ethyl]-3-phenylprop-2-enimidic acid
C21H23NO5 (369.15761480000003)
(9s)-9-(dimethylamino)-5,19-dimethoxy-15,17-dioxatetracyclo[10.7.0.0²,⁸.0¹⁴,¹⁸]nonadeca-1(12),2,4,7,13,18-hexaen-6-one
C21H23NO5 (369.15761480000003)
8-benzyl-2-(hexa-1,3-dien-1-yl)-6,8,9-trihydroxy-3-methyl-1-oxa-7-azaspiro[4.4]nona-2,6-dien-4-one
C21H23NO5 (369.15761480000003)
(1s,12s,13s)-17,18-dimethoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-2,4(8),9,14,16,18-hexaen-12-ol
C21H23NO5 (369.15761480000003)
(1s,12s)-9,15,16-trimethoxy-20-methyl-5,7-dioxa-20-azapentacyclo[10.7.1.0²,¹⁰.0⁴,⁸.0¹³,¹⁸]icosa-2(10),3,8,13(18),14,16-hexaene
C21H23NO5 (369.15761480000003)
(2e)-n-[(2s)-1-methoxy-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-(4-methoxyphenyl)prop-2-enimidic acid
C21H23NO5 (369.15761480000003)
9-(dimethylamino)-5,19-dimethoxy-15,17-dioxatetracyclo[10.7.0.0²,⁸.0¹⁴,¹⁸]nonadeca-1(12),2,4,7,13,18-hexaen-6-one
C21H23NO5 (369.15761480000003)
10-hydroxy-5-methyl-12-methylidene-3-oxo-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-18-yl acetate
C22H27NO4 (369.19399820000007)
(12br,13r)-3,4,10,11-tetramethoxy-13-methyl-7,8,12b,13-tetrahydro-5h-6-azatetraphene
C22H27NO4 (369.19399820000007)
5,6-dihydroxy-6-(1-hydroxyethyl)-4-isopropyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-ene-3,7-dione
6,7-dimethoxy-12-methyl-17,19-dioxa-12-azatetracyclo[12.7.0.0⁴,⁹.0¹⁶,²⁰]henicosa-1(21),4(9),5,7,14,16(20)-hexaen-3-one
C21H23NO5 (369.15761480000003)
(12bs)-3,4,10,11-tetramethoxy-7,8,12b,13-tetrahydro-6-azatetraphen-5-one
C21H23NO5 (369.15761480000003)
(1r,4s,5r,6r,7r,17r)-4,7-dihydroxy-4-(hydroxymethyl)-5,6,7-trimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-ene-3,8-dione
(12s)-2,16,17-trimethoxy-11-methyl-4,6-dioxa-11-azapentacyclo[10.7.1.0³,⁷.0⁸,²⁰.0¹⁴,¹⁹]icosa-1,3(7),8(20),14(19),15,17-hexaene
C21H23NO5 (369.15761480000003)
10-ethyl-14-methyl-3-(4-methyl-5-oxooxolan-2-yl)-12-oxa-4-azatetracyclo[7.6.1.0⁴,¹⁶.0¹¹,¹⁵]hexadeca-1(16),2,8-trien-13-one
C22H27NO4 (369.19399820000007)
5-({2-imino-1-[(4-methoxyphenyl)methyl]-3-methylimidazol-4-yl}methyl)-2-methoxybenzene-1,3-diol
C20H23N3O4 (369.16884780000004)
n-[2-(acetyloxy)-2-(3,4-dimethoxyphenyl)ethyl]-3-phenylprop-2-enimidic acid
C21H23NO5 (369.15761480000003)
4,7-dihydroxy-7-(hydroxymethyl)-4,5,6-trimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-ene-3,8-dione
1-hydroxy-2,4-dimethoxy-10-methyl-4-(3-methylbut-2-en-1-yl)acridine-3,9-dione
C21H23NO5 (369.15761480000003)
2-[(2-amino-1-hydroxypropylidene)amino]-3-[2-({hydroxy[4-oxo-3-(sec-butyl)oxetan-2-yl]methylidene}amino)cyclopropyl]propanoic acid
argemexicaine a
C21H23NO5 (369.15761480000003)
{"Ingredient_id": "HBIN016709","Ingredient_name": "argemexicaine a","Alias": "NA","Ingredient_formula": "C21H23NO5","Ingredient_Smile": "CN1CCC2=CC3=C(C=C2C(=O)CC4=C(C1)C=CC(=C4OC)OC)OCO3","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1665","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
argemexicaine b
C21H23NO5 (369.15761480000003)
{"Ingredient_id": "HBIN016710","Ingredient_name": "argemexicaine b","Alias": "NA","Ingredient_formula": "C21H23NO5","Ingredient_Smile": "CN1CCC2=C(C(=O)CC3=CC4=C(C=C3C1)OCO4)C(=C(C=C2)OC)OC","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1666","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
baicalidine
C21H23NO5 (369.15761480000003)
{"Ingredient_id": "HBIN017514","Ingredient_name": "baicalidine","Alias": "NA","Ingredient_formula": "C21H23NO5","Ingredient_Smile": "NA","Ingredient_weight": "369.41","OB_score": "42.62849499","CAS_id": "83008-39-3","SymMap_id": "SMIT10009","TCMID_id": "NA","TCMSP_id": "MOL008786","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(1r,4s,5r,6r,7s,17r)-4,7-dihydroxy-7-(hydroxymethyl)-4,5,6-trimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-ene-3,8-dione
(3'as,6'r,6'ar)-3'a-hydroxy-2'-imino-6'a-methoxy-6'-(4-methoxyphenyl)-3'-methyl-4',6'-dihydro-1'h-spiro[cyclohexane-1,5'-cyclopenta[d]imidazole]-2,5-dien-4-one
C20H23N3O4 (369.16884780000004)
(1r,6s,17r)-4,7-dihydroxy-4-(hydroxymethyl)-5,6,7-trimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-ene-3,8-dione
(1r,7ar)-7-({[(2r,3s)-2,3-dihydroxy-2-(hydroxymethyl)butanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 3-methylbut-2-enoate
(1s,13s,15s)-7-chloro-12,12-dimethyl-10,19,21-triazahexacyclo[13.5.2.0¹,¹³.0³,¹¹.0⁴,⁹.0¹⁵,¹⁹]docosa-3(11),4,6,8,21-pentaen-22-ol
7-chloro-12,12-dimethyl-10,19,21-triazahexacyclo[13.5.2.0¹,¹³.0³,¹¹.0⁴,⁹.0¹⁵,¹⁹]docosa-3(11),4,6,8,21-pentaen-22-ol
(6s,7s)-1-[2,4-dihydroxy-5-(4-hydroxyphenyl)pyridin-3-yl]-7-hydroxy-4,6-dimethylocta-2,4-dien-1-one
C21H23NO5 (369.15761480000003)
(2r)-2-{[(3ar,8as)-3a-hydroxy-2h,3h,8ah-furo[2,3-b]indol-8-yl]methyl}-4-butyl-2,5-dimethylcyclopent-4-ene-1,3-dione
C22H27NO4 (369.19399820000007)
6',8-dimethoxy-2'-methyl-3',4',6,8-tetrahydro-2h-spiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-7'-ol
C21H23NO5 (369.15761480000003)
n-[1-methoxy-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-(4-methoxyphenyl)prop-2-enimidic acid
C21H23NO5 (369.15761480000003)
1,6-dihydroxy-3,5-dimethoxy-10-methyl-4-(3-methylbut-2-en-1-yl)acridin-9-one
C21H23NO5 (369.15761480000003)
(1r,4r,5s,6r,16r)-5,6-dihydroxy-6-[(1s)-1-hydroxyethyl]-4-isopropyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-ene-3,7-dione
methyl (9s)-4,15,16-trimethoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,13,15-hexaene-10-carboxylate
C21H23NO5 (369.15761480000003)
(1s,4r,5r,6s,16r)-5,6-dihydroxy-6-[(1s)-1-hydroxyethyl]-4-isopropyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-ene-3,7-dione
7,8-dimethoxy-12-methyl-17,19-dioxa-12-azatetracyclo[12.7.0.0⁴,⁹.0¹⁶,²⁰]henicosa-1(21),4,6,8,14,16(20)-hexaen-2-one
C21H23NO5 (369.15761480000003)
(2e,4e,6s)-1-[2,4-dihydroxy-5-(4-hydroxyphenyl)pyridin-3-yl]-6-(hydroxymethyl)-4-methylocta-2,4-dien-1-one
C21H23NO5 (369.15761480000003)
17,18,19-trimethoxy-13-methyl-5,7-dioxa-13-azapentacyclo[10.7.1.0²,¹⁰.0⁴,⁸.0¹⁶,²⁰]icosa-1(20),2,4(8),9,16,18-hexaene
C21H23NO5 (369.15761480000003)
(7r,8r)-6',7'-dimethoxy-2'-methyl-3',4',6,8-tetrahydro-2h-spiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-8-ol
C21H23NO5 (369.15761480000003)
(2s)-2-{[(3ar)-3a-hydroxy-2h,3h,8ah-furo[2,3-b]indol-8-yl]methyl}-4-butyl-2,5-dimethylcyclopent-4-ene-1,3-dione
C22H27NO4 (369.19399820000007)
(5s)-3,4,10,11-tetramethoxy-7,8-dihydro-5h-6-azatetraphen-5-ol
C21H23NO5 (369.15761480000003)
7-(2-hydroxyethyl)-5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-6,16,19-trione
C22H27NO4 (369.19399820000007)
(1r,5r,8r,9s,10r,11s,14s,16s,17r,18s)-10-hydroxy-5-methyl-12-methylidene-3-oxo-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-18-yl acetate
C22H27NO4 (369.19399820000007)
(1r,4r,5r,6r,16r)-5,6-dihydroxy-6-[(1r)-1-hydroxyethyl]-4-isopropyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-ene-3,7-dione
(1s,2s,5r,6r,10s,12s,13r,16r,18s)-6,9-dihydroxy-5,12,16-trimethyl-8-azapentacyclo[10.8.0.0²,¹⁰.0⁶,¹⁰.0¹³,¹⁸]icosa-3,8,19-triene-7,11-dione
C22H27NO4 (369.19399820000007)
(2s)-2-{[(2s)-2-amino-1-hydroxypropylidene]amino}-3-[(1s,2s)-2-({[(2r)-3-[(2s)-butan-2-yl]-4-oxooxetan-2-yl](hydroxy)methylidene}amino)cyclopropyl]propanoic acid
(4r)-1-hydroxy-2,4-dimethoxy-10-methyl-4-(3-methylbut-2-en-1-yl)acridine-3,9-dione
C21H23NO5 (369.15761480000003)
(1s,4r,6s,7s,17r)-4,7-dihydroxy-4-[(1s)-1-hydroxyethyl]-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-ene-3,8-dione
(5r)-5-[(4-hydroxyphenyl)methyl]-2-imino-5-[(s)-methoxy(4-methoxyphenyl)methyl]-3-methylimidazolidin-4-one
C20H23N3O4 (369.16884780000004)
3-[(2e,4e,6s)-4,6-dimethylocta-2,4-dienoyl]-1,4-dihydroxy-5-(4-hydroxyphenyl)pyridin-2-one
C21H23NO5 (369.15761480000003)
2,3-dimethoxy-6-({6-methyl-2h,5h,7h,8h-[1,3]dioxolo[4,5-g]isoquinolin-5-yl}methyl)benzaldehyde
C21H23NO5 (369.15761480000003)
3,4,10,11-tetramethoxy-7,8,12b,13-tetrahydro-6-azatetraphen-5-one
C21H23NO5 (369.15761480000003)
4,7-dihydroxy-4-(1-hydroxyethyl)-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-ene-3,8-dione
6',7'-dimethoxy-2'-methyl-3',4',6,8-tetrahydro-2h-spiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-8-ol
C21H23NO5 (369.15761480000003)
5,6-dimethoxy-11-methyl-17,19-dioxa-11-azatetracyclo[12.7.0.0⁴,⁹.0¹⁶,²⁰]henicosa-1(21),4,6,8,14,16(20)-hexaen-2-one
C21H23NO5 (369.15761480000003)
17,18-dimethoxy-21-methyl-5,7-dioxa-21-azapentacyclo[11.8.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁹]henicosa-2,4(8),9,14,16,18-hexaen-12-ol
C21H23NO5 (369.15761480000003)
(12r)-7,16,17-trimethoxy-11-methyl-3,5-dioxa-11-azapentacyclo[10.7.1.0²,⁶.0⁸,²⁰.0¹⁴,¹⁹]icosa-1,6,8(20),14(19),15,17-hexaene
C21H23NO5 (369.15761480000003)
7-({[2,3-dihydroxy-2-(hydroxymethyl)butanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 3-methylbut-2-enoate
1-[2,4-dihydroxy-5-(4-hydroxyphenyl)pyridin-3-yl]-2-[(2s,5s,6s)-3,5,6-trimethyl-5,6-dihydro-2h-pyran-2-yl]ethanone
C21H23NO5 (369.15761480000003)
(10s,11r,14r,15s)-10-ethyl-14-methyl-3-[(2r,4r)-4-methyl-5-oxooxolan-2-yl]-12-oxa-4-azatetracyclo[7.6.1.0⁴,¹⁶.0¹¹,¹⁵]hexadeca-1(16),2,8-trien-13-one
C22H27NO4 (369.19399820000007)
(1r,5s,8r,9s,10s,11s,14s,16s,17r,18s)-10-hydroxy-5-methyl-12-methylidene-3-oxo-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-18-yl acetate
C22H27NO4 (369.19399820000007)
1-[2,4-dihydroxy-5-(4-hydroxyphenyl)pyridin-3-yl]-6-(hydroxymethyl)-4-methylocta-2,4-dien-1-one
C21H23NO5 (369.15761480000003)
6,7-dimethoxy-11-methyl-17,19-dioxa-11-azatetracyclo[12.7.0.0⁴,⁹.0¹⁶,²⁰]henicosa-1(21),4(9),5,7,14,16(20)-hexaen-2-one
C21H23NO5 (369.15761480000003)
1-[(3,4-dimethoxyphenyl)(methoxy)methyl]-6,7-dimethoxyisoquinoline
C21H23NO5 (369.15761480000003)
4-hydroxy-n-[(3s,5r)-2-hydroxy-3-[(4-hydroxyphenyl)methyl]-3,4,5,6,7,8-hexahydro-1,4-diazocin-5-yl]benzamide
C20H23N3O4 (369.16884780000004)
4-ethylidene-7,12-dihydroxy-6,7-dimethyl-3,8-dioxo-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadecan-14-ium-14-olate
(2z)-n-[(2s)-1-methoxy-3-(4-methoxyphenyl)-1-oxopropan-2-yl]-3-(4-methoxyphenyl)prop-2-enimidic acid
C21H23NO5 (369.15761480000003)
3-[(2e,4e)-4,6-dimethylocta-2,4-dienoyl]-1,2-dihydroxy-5-(4-hydroxyphenyl)pyridin-4-one
C21H23NO5 (369.15761480000003)
6-(1h-indol-3-ylmethyl)-3-isopropyl-5-[(1e)-2-phenylethenyl]-1h-pyrazin-2-one
(2e,4e)-1-[2,4-dihydroxy-5-(4-hydroxyphenyl)pyridin-3-yl]-6-(hydroxymethyl)-4-methylocta-2,4-dien-1-one
C21H23NO5 (369.15761480000003)
(1r,5r)-4,7-dihydroxy-7-(hydroxymethyl)-4,5,6-trimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-ene-3,8-dione
(1s,5r,8r,9s,11r,14s,17s,18r)-7-(2-hydroxyethyl)-5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-6,16,19-trione
C22H27NO4 (369.19399820000007)
2-hydroxy-3,10,11-trimethoxy-7,8,12b,13-tetrahydro-5h-6-azatetraphene-1-carbaldehyde
C21H23NO5 (369.15761480000003)
4,5,15,16-tetramethoxy-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2(7),3,5,8,13,15-heptaen-8-ol
C21H23NO5 (369.15761480000003)
dimethyl[2-(3,4,7,8-tetramethoxyphenanthren-1-yl)ethyl]amine
C22H27NO4 (369.19399820000007)
(1s,13s,15s)-6-chloro-12,12-dimethyl-10,19,21-triazahexacyclo[13.5.2.0¹,¹³.0³,¹¹.0⁴,⁹.0¹⁵,¹⁹]docosa-3(11),4,6,8,21-pentaen-22-ol
6-(1h-indol-3-ylmethyl)-3-isopropyl-5-[(1z)-2-phenylethenyl]-1h-pyrazin-2-one
(2e)-3-(2h-1,3-benzodioxol-5-yl)-n-[2-(3,4-dimethoxyphenyl)ethyl]-n-methylprop-2-enamide
C21H23NO5 (369.15761480000003)
1-[4-hydroxy-3-methoxy-2-methyl-6-(3-methylbut-2-en-1-yl)-9h-carbazol-1-yl]propane-1,2-diol
C22H27NO4 (369.19399820000007)
(1r)-7-({[2,3-dihydroxy-2-(hydroxymethyl)butanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2z)-2-methylbut-2-enoate
(12s)-7,16,17-trimethoxy-11-methyl-3,5-dioxa-11-azapentacyclo[10.7.1.0²,⁶.0⁸,²⁰.0¹⁴,¹⁹]icosa-1,6,8(20),14(19),15,17-hexaene
C21H23NO5 (369.15761480000003)
(1r,4s,6r,7r,17r)-4,7-dihydroxy-4-[(1r)-1-hydroxyethyl]-6,7-dimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-ene-3,8-dione
(1r,4r,5s,6r,16s)-5,6-dihydroxy-6-[(1s)-1-hydroxyethyl]-4-isopropyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-ene-3,7-dione
(2e)-3-[(3r)-3-nonyloxiran-2-yl]-1-[(3r,4s,5s)-2,3,4-trihydroxy-5-(hydroxymethyl)-4,5-dihydropyrrol-3-yl]prop-2-en-1-one
dimethyl[2-(3,4,6,7-tetramethoxyphenanthren-1-yl)ethyl]amine
C22H27NO4 (369.19399820000007)
(2e,4z,6s,7s)-1-[2,4-dihydroxy-5-(4-hydroxyphenyl)pyridin-3-yl]-7-hydroxy-4,6-dimethylocta-2,4-dien-1-one
C21H23NO5 (369.15761480000003)
2-{1,2-dimethoxy-9h-phenanthro[2,3-d][1,3]dioxol-4-yl}-n,n-dimethylethanamine oxide
C21H23NO5 (369.15761480000003)
3-[(2e,4e)-4,6-dimethylocta-2,4-dienoyl]-1,4-dihydroxy-5-(4-hydroxyphenyl)pyridin-2-one
C21H23NO5 (369.15761480000003)
5,6-dihydroxy-4-(2-hydroxypropan-2-yl)-5,6-dimethyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-ene-3,7-dione
(2r,3r,4s,5s,6r)-2-(hydroxymethyl)-1-methyl-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)piperidine-3,4,5-triol
C14H27NO10 (369.16348819999996)
(12br)-3,4,10,11-tetramethoxy-13-methyl-7,8,12b,13-tetrahydro-5h-6-azatetraphene
C22H27NO4 (369.19399820000007)
(2e,4e,6s,7s)-1-[2,4-dihydroxy-5-(4-hydroxyphenyl)pyridin-3-yl]-7-hydroxy-4,6-dimethylocta-2,4-dien-1-one
C21H23NO5 (369.15761480000003)
2,15-dihydroxy-11-methoxy-14-methyl-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10,15-pentaen-12-one
C20H23N3O4 (369.16884780000004)
(1s,9r,14s)-2,15-dihydroxy-11-methoxy-14-methyl-9-(2-methylbut-3-en-2-yl)-2,13,16-triazatetracyclo[7.7.0.0¹,¹³.0³,⁸]hexadeca-3,5,7,10,15-pentaen-12-one
C20H23N3O4 (369.16884780000004)
(2s)-2-{[(3ar,8as)-3a-hydroxy-2h,3h,8ah-furo[2,3-b]indol-8-yl]methyl}-4-butyl-2,5-dimethylcyclopent-4-ene-1,3-dione
C22H27NO4 (369.19399820000007)
3-(2h-1,3-benzodioxol-5-yl)-n-[2-(3,4-dimethoxyphenyl)ethyl]-n-methylprop-2-enamide
C21H23NO5 (369.15761480000003)
(2r,3s,4r)-2-[(s)-(1s)-cyclohex-2-en-1-yl(hydroxy)methyl]-3,5-dihydroxy-4-(1-hydroxyhexyl)-3-methyl-4h-pyrrole-2-carboxylic acid
15,16,17-trimethoxy-11-methyl-3,5-dioxa-11-azapentacyclo[10.7.1.0²,⁶.0⁸,²⁰.0¹⁴,¹⁹]icosa-1,6,8(20),14(19),15,17-hexaene
C21H23NO5 (369.15761480000003)
7,8-dimethoxy-2-methyl-17,19-dioxa-2-azatetracyclo[12.7.0.0⁵,¹⁰.0¹⁶,²⁰]henicosa-1(21),5(10),6,8,14,16(20)-hexaen-11-one
C21H23NO5 (369.15761480000003)
21-hydroxy-5-methyl-15-methylidene-7-oxa-10-azaheptacyclo[12.6.2.0¹,¹¹.0⁵,²⁰.0⁶,¹⁰.0¹²,¹⁷.0¹⁷,²¹]docosane-19,22-dione
C22H27NO4 (369.19399820000007)
4-(hydroxymethyl)-7-methyl-8-[3-methyl-3-(3-methylbutyl)oxiran-2-yl]-9h-carbazole-1,6-diol
C22H27NO4 (369.19399820000007)
7,16,17-trimethoxy-11-methyl-3,5-dioxa-11-azapentacyclo[10.7.1.0²,⁶.0⁸,²⁰.0¹⁴,¹⁹]icosa-1,6,8(20),14(19),15,17-hexaene
C21H23NO5 (369.15761480000003)
(7r,8r)-6',8-dimethoxy-2'-methyl-3',4',6,8-tetrahydro-2h-spiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-7'-ol
C21H23NO5 (369.15761480000003)
5-hydroxy-6,7-dimethoxy-4-(5-phenylpentyl)-1h-indole-2,3-dione
C21H23NO5 (369.15761480000003)
(1r,7as)-7-({[(2r,3s)-2,3-dihydroxy-2-(hydroxymethyl)butanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2z)-2-methylbut-2-enoate
9,15,16-trimethoxy-20-methyl-5,7-dioxa-20-azapentacyclo[10.7.1.0²,¹⁰.0⁴,⁸.0¹³,¹⁸]icosa-2(10),3,8,13(18),14,16-hexaene
C21H23NO5 (369.15761480000003)
2-({3a-hydroxy-2h,3h,8ah-furo[2,3-b]indol-8-yl}methyl)-4-butyl-2,5-dimethylcyclopent-4-ene-1,3-dione
C22H27NO4 (369.19399820000007)
(5r,8r,9r)-8-benzyl-2-[(1e,3e)-hexa-1,3-dien-1-yl]-6,8,9-trihydroxy-3-methyl-1-oxa-7-azaspiro[4.4]nona-2,6-dien-4-one
C21H23NO5 (369.15761480000003)
2,16,17-trimethoxy-11-methyl-4,6-dioxa-11-azapentacyclo[10.7.1.0³,⁷.0⁸,²⁰.0¹⁴,¹⁹]icosa-1,3(7),8(20),14(19),15,17-hexaene
C21H23NO5 (369.15761480000003)
(2s)-2-{[(2s)-2-amino-1-hydroxypropylidene]amino}-3-[(1r,2s)-2-({hydroxy[(3s)-4-oxo-3-(sec-butyl)oxetan-2-yl]methylidene}amino)cyclopropyl]propanoic acid
(1r,4s,5r,6r,16r)-5,6-dihydroxy-6-[(1s)-1-hydroxyethyl]-4-isopropyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-ene-3,7-dione
5,6-dimethoxy-12-methyl-17,19-dioxa-12-azatetracyclo[12.7.0.0⁴,⁹.0¹⁶,²⁰]henicosa-1(21),4,6,8,14,16(20)-hexaen-3-one
C21H23NO5 (369.15761480000003)
(2s)-2-{[(2s)-2-amino-1-hydroxypropylidene]amino}-3-[(1r,2s)-2-({[(2r,3s)-3-[(2s)-butan-2-yl]-4-oxooxetan-2-yl](hydroxy)methylidene}amino)cyclopropyl]propanoic acid
4,15,16-trimethoxy-20-methyl-6,8-dioxa-20-azapentacyclo[10.7.1.0²,¹⁰.0⁵,⁹.0¹³,¹⁸]icosa-2(10),3,5(9),13(18),14,16-hexaene
C21H23NO5 (369.15761480000003)
4,7-dihydroxy-4-(hydroxymethyl)-5,6,7-trimethyl-2,9-dioxa-14-azatricyclo[9.5.1.0¹⁴,¹⁷]heptadec-11-ene-3,8-dione
methyl 4,15,16-trimethoxy-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2,4,6,13,15-hexaene-10-carboxylate
C21H23NO5 (369.15761480000003)
3,4,10,11-tetramethoxy-7,8-dihydro-5h-6-azatetraphen-5-ol
C21H23NO5 (369.15761480000003)
(12s)-15,16,17-trimethoxy-11-methyl-3,5-dioxa-11-azapentacyclo[10.7.1.0²,⁶.0⁸,²⁰.0¹⁴,¹⁹]icosa-1,6,8(20),14(19),15,17-hexaene
C21H23NO5 (369.15761480000003)
(8s)-6',7'-dimethoxy-2'-methyl-3',4',6,8-tetrahydro-2h-spiro[indeno[4,5-d][1,3]dioxole-7,1'-isoquinolin]-8-ol
C21H23NO5 (369.15761480000003)
7-({[2,3-dihydroxy-2-(hydroxymethyl)butanoyl]oxy}methyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 2-methylbut-2-enoate
3-(4,6-dimethylocta-2,4-dienoyl)-1,4-dihydroxy-5-(4-hydroxyphenyl)pyridin-2-one
C21H23NO5 (369.15761480000003)
(2e,4e,6r)-1-[2,4-dihydroxy-5-(4-hydroxyphenyl)pyridin-3-yl]-6-(hydroxymethyl)-4-methylocta-2,4-dien-1-one
C21H23NO5 (369.15761480000003)
12,16-dimethoxy-21-methyl-4,6-dioxa-21-azapentacyclo[10.9.0.0²,¹⁰.0³,⁷.0¹³,¹⁸]henicosa-2,7,9,13(18),14,16-hexaen-15-ol
C21H23NO5 (369.15761480000003)